# US 2014/0193335 A1 · Devices and methods for the treatment of cancer > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0193335 A1 - Document ID: US20140193335A1 - Status: Published application - Kind: A1 - Application number: 14/149,881 - Filed: 2014-01-08 - Published: 2014-07-10 - Earliest claimed: 2001-02-22 - Assignees: Enigma Therapeutics Limited - Applicants: Enigma Therapeutics Limited - Inventors: Roger ASTON; Leigh T. CANHAM - Web page: https://patentgrep.com/patent/US20140193335A1 ## CPC - A61K 51/1244: {microparticles or nanoparticles, e.g. polymeric nanoparticles} - A61K 41/009: {Neutron capture therapy, e.g. using uranium or non-boron material} - A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb} - A61K 51/02: characterised by the carrier {, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus} - A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics - A61P 13/12: of the kidneys - A61P 15/14: for lactation disorders, e.g. galactorrhoea - A61P 25/00: Drugs for disorders of the nervous system - A61P 35/00: Antineoplastic agents - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The invention relates to the treatment of cancer. In particular the invention relates to an internal therapeutic product comprising: (i) an anti-cancer component selected from one or both of: a radionucleotide, a cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable silicon, biocompatible silicon, bioactive silicon, porous silicon, polycrystalline silicon, amorphous silicon, and bulk crystalline silicon, the internal therapeutic product being for the treatment of cancer. ## Claims ### Claim 1 An internal therapeutic product comprising: (i) an anti-cancer component comprising at least one radionucleotide and/or at least one cytotoxic drug; and (ii) a silicon component selected from one or more of: resorbable silicon, biocompatible silicon, bioactive silicon, porous silicon, polycrystalline silicon, amorphous silicon, and bulk crystalline silicon. ### Claim 2 (depends on 1) An internal therapeutic product according to claim 1 characterised in that therapeutic product comprises at least one implant. ### Claim 3 (depends on 2) An internal therapeutic product according to claim 2 wherein the or at least one is of the implants comprises at least part of the silicon component and at least part of the anti-cancer component. ### Claim 4 (depends on 1) An internal therapeutic product according to claim 1 characterised in that the silicon component comprises resorbable silicon. ### Claim 5 (depends on 1) An internal therapeutic product according to claim 1 characterised in that the silicon component comprises resorbable silicon and the anti-cancer component comprises a radionucleotide, the radionucleotide being distributed through at least part of the resorbable silicon. ### Claim 6 (depends on 3) An internal therapeutic product according to claim 3 characterised in that the or at least one of the implants comprises resorbable silicon and a radionucleotide, the resorbable silicon having a structure and composition such that substantially all the radionucleotide remains in and/or on at least part of the or at least one of the implants for a period, measured from the time of implantation, greater than the half life of the radionucleotide. ### Claim 7 (depends on 3) An internal therapeutic product according to claim 3 characterised in that the or at least one of the implants may comprise resorbable silicon and a cytotoxic drug, the resorbable silicon having a structure and composition such that the implant remains sufficiently intact to substantially localise the drug release at the site of the implant. ### Claim 8 (depends on 1) An internal therapeutic product according to claim 1 characterised in that anti-cancer agent comprises a radionucleotide, and the radionucleotide is selected from one or more of: 90Y, 32P, 124Sb, 114In, 59Fe, 76As, 140La, 47Ca, 103Pd, 89Sr, 131I, 125I, 60Co, 192Ir, and 198Au. ### Claim 9 A method of treating a cancer, the method comprising the step of introducing an internal therapeutic product into a patient, the internal therapeutic product comprising: (i) a silicon component selected from one or more of: resorbable silicon, biocompatible silicon, bioactive silicon, porous silicon, polycrystalline silicon, amorphous silicon, bulk crystalline silicon; and (ii) an anti-cancer component comprises at least one radionucleotide and/or at least one cytotoxic drug. ### Claim 10 (depends on 9) A method according to claim 9 characterised in that the internal therapeutic product comprises at least one implant, the step of introducing the internal therapeutic product comprising the step of implanting the or at least one of the implants into the body of a patient. ### Claim 11 (depends on 10) A method according to claim 10 characterised in that the or at least one of the implants comprises at least part of the silicon component and at least part of the anti-cancer component. ### Claim 12 (depends on 11) A method according to claim 11 characterised in that the or at least one of the implants comprises resorbable silicon and a cytotoxic drug, the method of treating a cancer comprising the further step of releasing at least part of the cytotoxic drug in such a manner that the release of the cytotoxic drug remains substantially localised to the point of implantation. ### Claim 13 (depends on 11) A method according to claim 11 characterised in that the or at least one of the implants comprises resorbable silicon and a radionucleotide, the method of treating a cancer comprising the step of treating part of the patient's body with radiation from the radionucleotide in such a manner that the radiation treatment is localised to the point of implantation, and comprising the further step of allowing the silicon to substantially completely resorb once the half life of the radionucleotide has been exceeded. ### Claim 14 (depends on 9) A method according to claim 9 characterised in that the internal therapeutic product comprises a radionucleotide and a cytotoxic drug and the method of is treating cancer comprises the further step of combining the radionucleotide and the cytotoxic agent less than 10 hours prior the introduction of the therapeutic product to the patient. ### Claim 15 (depends on 1) An internal therapeutic product according to claim 1 characterised in that the anti-cancer component comprise a radionucleotide having a structure and composition obtainable by the transmutation of porous silicon. ### Claim 16 (depends on 1) An internal therapeutic product according to claim 1 characterised in that the anti-cancer component comprise a radionucleotide having a structure and composition obtainable by the transmutation of germanium atoms that form part of a porous silicon germanium alloy.